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ABSTRACT
Maintenance of normal maternal thyroxinemia prevents severe triiodothyronine (T3) deficiency of the fetus with
primary thyroid failure (1). We have studied whether thyroxine (T4) would also protect the fetal brain when ma-
ternal hypothyroxinemia is caused by nonthyroidal illnesses. We have used the streptozotocin-induced diabetes
mellitus pregnant rat as a model of maternal nonthyroidal illness. We measured the effects of diabetes mellitus,
and of correction of the ensuing maternal hypothyroxinemia with T4 as compared to insulin, on maternal body
weight, the outcome of pregnancy, glucose, insulin, T4, T3, reverse T3, and thyrotropin levels in the maternal and
fetal circulation, as well as T4 and T3 concentrations in tissues, and iodothyronine deiodinases in liver, lung, and
brain. The diabetic mothers showed changes in thyroid hormone status typical of nonthyroidal illnesses. Thyroid
hormone status of the fetuses was severely affected: the total T4 and T3 pools decreased to one-third of normal
values. T4 and T3 concentrations in the fetal brain were lower than normal and the expected increase in 5'-deio-
dinase activity was not observed. Although insulin treatment avoided or mitigated these changes, the low cere-
bral T3 did not improve with T4 treatment of the maternal hypothyroxinemia. Several findings indicated that
treatment of the severely ill dams with T4 was actually harmful for the outcome of pregnancy. These negative ef-
fects were observed without the expected increase in the maternal or fetal T3 pools.
INTRODUCTION feet of the maternal T4 would explain the lack of major
brain damage of most hypothyroid fetuses at birth, in con-
THYROXiNE (T4) and 3,5,3'-triiodothyronine (T3) con- trast with the irreversible central nervous system damagecentrations are very low in all tissues of rat fetuses observed in the neurological cretin. The mother of the lat-
from dams with methimazole (MMI)-induced primary thy- ter is severely hypothyroxinemic, and does not offer any
roid failure. If the maternal hypothyroxinemia is avoided protection to the fetal brain, which is therefore markedly
by treatment with T4, the brain is preferentially protected T3 deficient before birth, despite the expected increase in
against the deficiency of T3 until birth (1): fetal brain T3 5'D-II activity (3). Both in the neurological cretin (4) and
reaches normal concentrations, despite lower than normal in the experimental model of rats fed a diet with a very
fetal serum T4 and increased TSH levels. T4 is by far the low iodine content (3), maternal circulating T3 is normal,
main source of cerebral T3 in the rat fetus (1,2); changes but this does not improve fetal brain T3 concentrations un-
in circulating T3 hardly affect cerebral T3 within a physi- less the maternal hypothyroxinemia is also corrected,
ological range of serum T3 levels. Both the capacity of cere- These findings have drawn attention to the importance
bral type II 5'-iodothyroninedeiodinase (5'D-II) to respond of maintaining normal maternal T4 levels during preg-
to low fetal serum T4 with a marked increase in its activ- nancy, even when normal T3 levels might prevent the ap-
ity and the amount of T4 transferred from the mother to pearance of clinical hypothyroidism. We already cautioned
the fetus play crucial roles in maintaining T3 homeostasis (1), however, against extrapolation of this conclusion to
in the brain of the hypothyroid fetus. This protective ef- other situations where changes in maternal and fetal thy-
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roid hormone status might not be due to primary thyroid
failure or an inadequate iodine supply, but to other causes,
such as "nonthyroidal" illness. This might interfere with
the transfer of T4 from the mother to the fetus, the re-
sponses of fetal deiodinating enzymes, or other mecha-
nism(s) contributing to fetal cerebral T3 homeostasis.
Moreover, the possibility exists that treatment with T4
might actually be harmful in such conditions, as the de-
creased hormonal secretion by the thyroid is considered as
a protective mechanism against energy loss and excessive
catabolism (5-7).
Diabetes mellitus is considered as a nonthyroidal disease
leading to alterations of thyroid hormone status typical of
the so called "low T3 syndrome" (5-8). The major alter-
ations in thyroid hormone economy are a reduction in the
TSH stimulation of the thyroid gland, probably caused by
"central" hypothyroidism, and in the peripheral genera-
tion of T3 from T4 (8). The injection of streptozotocin(STZ) in rats is frequently used to obtain an experimental
model for the study of nonthyroidal illness, by inducing
diabetes mellitus.
In the STZ-diabetic adult rat, as in other situations of
nonthyroidal illness, both the thyroidal secretion of T4 and
T3 and the extrathyroidal monodeiodination of T4 to T3
are clearly impaired, as a consequence of which circulat-
ing T4 and T3 are very low, as well as the concentrations
of both iodothyronines in most tissues (5-10). To our
knowledge little is known about the possible influence of
maternal diabetes on the thyroid hormone status of the fe-
tus, except for a preliminary study from our group (11)
showing that STZ-induced maternal diabetes mellitus also
affects fetal thyroid hormone economy, causing a decrease
of T4 and T3 in plasma and most fetal tissues, brain in-
cluded, with possible impairment of the normal response
of 5'D-II to low T4 concentrations. These alterations were
mitigated or avoided by appropriate treatment of the dams
with insulin.
The present study has been undertaken to assess the po-
tential benefits for the fetus of the correction of maternal
hypothyroxinemia when caused by nonthyroidal illness.
The underlying cause of the maternal hypothyroxinemia
might not be readily ascertained or treated, and treatment
with T4 might be attempted to normalize maternal T4 lev-
els, in view of the beneficial effects of this treatment for
fetal brain T3 in case of primary thyroid failure (1). Dia-
betes mellitus was used as a model of nonthyroidal illness.
As will be seen, T4 treatment, without correction of the di-
abetic state, is of no benefit for fetal tissues, brain included,
and actually appears to be harmful both for the mother
and for the outcome of pregnancy.
MATERIALS AND METHODS
Experimental design
Female Wistar rats were used for this study. The guide-
lines for humane treatment of animals were followed in
compliance with the principles outlined in "The care and
use of animals" and the study was approved by the com-
mittee of our Institute. They were maintained at 22°C with
12-h periods of light and darkness and fed ad libitum with
a standard diet (18 g protein, 39 g carbohydrate, 2.5 g
lipid, and 4.5 g cellulose/100 g plus salt and vitamin mix-
tures, with an estimated caloric content of 2.54 kcal/g).
They were mated with normal males and the morning of
appearance of the vaginal plus was considered as day 0 of
gestation. Twenty-four pregnant rats were divided into
four groups. One group served as normal pregnant con-
trols (C). At day 7 of gestation, the other three groups of
rats (D groups) were injected into the femoral vein with
4.5 mg/100 g body weight (BW) of streptozotocin (STZ)
dissolved in 50 mM citrate buffer, pH 4.5 (12). From the
three groups of D rats, one was left without further treat-
ment (D group), a second group was treated with insulin(D+Ins), and a third group with T4 (D + T4). The group
of D+Ins dams was injected sc once daily with 0.5 U bovine
insulin/100 g BW/day from 9 to 20 days of gestation (dg).
The group of D+T4 dams was implanted under the dor-
sal skin with Alzet 2ML2 osmotic minipumps (Alza Co.
Palo Alto, CA) delivering at a constant rate 2.4 pg TV100
g BW/day from 9 to 21 dg. The infusion of T4 was carried
out as already described (1) with modifications: T4 (free
acid form, Sigma Chemicals Co, St. Louis, MO) was dis-
solved in the minimum volume of 0.05 N NaOH and then
taken to the required volume in 50% propylene glycol.
At 21 dg all dams were anesthetized with ether, bled,
and perfused with 40-50 mL of 0.05 M phosphosaline
buffer, pH 7.4, as described (1). Maternal plasma, liver,
brain, heart, lung, and mamma were obtained and frozen.
The uterus was dissected out and carefully rinsed and blot-
ted free of maternal blood. The fetuses were then dissected
out, bled, separated from the placenta, weighed, and im-
mediately placed on ice. The fetal brain, liver, and lung
were dissected out and quickly frozen on dry ice; the thy-
roid, adhering to the trachea, was withdrawn and frozen.
The placentas were separated, weighed, and divided into
the basal (maternal) and labyrinthine (fetal) sides with
blunt forceps and frozen rapidly, as described (1,13).
Determination of thyroid hormone concentrations
Thyroid hormones were determined by RIAs after ex-
traction and purification of plasma and tissues (14—17). In
brief, methanol is added to the still frozen tissue sample
and homogenized with tracer amounts of [131I]T4 and
ri25T]Y3 being added to each homogenate. This is followed
by extraction of more than 90% of the endogenous and
added iodothyronines using chloroform-methanol (2:1).
The iodothyronines are then backextracted into an aque-
ous phase, and purified by passing this aqueous phase
through Bio-Rad AG 1x2 resin columns. After a pH gra-
dient, the iodothyronines are eluted with 70% acetic acid,
which is then evaporated to dryness and dissolved in RIA
buffer. Each extract is extensively counted to determine the
recovery of the [131I]T4 and [125I]T3 added to each sample
during the initial homogenization process. Average recov-
ery is 50-60% for [131I]T4 and 60-70% for [125I]T3. The
samples are submitted to highly sensitive RIAs for the de-
termination of T4 and T3, the limits of sensitivity being 2.5
pg T4 and 1.5 pg T3/tube. Each sample is processed in du-
plicate or triplicate at two or more dilutions. Concentra-
tions are then calculated using the amounts of T4 and T3
found in the respective RIAs, the individual recovery of the
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[131I]T4 and [125I]T3 added to each sample during the ini-
tial homogenization process, and the weight of the tissue
sample submitted to extraction.
Maternal samples were processed individually. Plasma
from different fetuses were pooled to obtain 300-400 pL
aliquots. Fetal tissues were pooled (2 to 3 organs per pool)
for the determination of T4 and T3. Pools were always ob-
tained from fetuses of the same litter.
Percentage of circulating "free" T4 and T3
The method described by Mendel et al. (18) was used,
with modifications. High specific activity [125I]T4 or[125I]T3 (approximately 300,000 cpm) was added in a 5 pL
volume to 300 pL of plasma, and incubated at room tem-
perature for 1 h. A 280-/J.L aliquot of each was submitted
to ultrafiltration using Microcon 10 microconcentrators(Amicon Division, W.R. Grace and Co, Beverly, MA) and
a 20 min centrifugation at 14,000 rpm. A measured vol-
ume of each ultrafiltrate was added to 0.5 mL bovine serum
and submitted to precipitation with 10% trichloroacetic
acid (TCA) and centrifuged, the pellet being washed twice
with the same solution of TCA. The washed pellet was
counted and its radioactivity calculated as percentage of the
initial added tracer, submitted to the same TCA precipita-
tion and washing procedure. This percentage of "free" T4(% FT4) or "free" T3 (% FT3) and the T4 and T3 concen-
trations determined by RIA were used to calculate the con-
centrations of free T4 (FT4) or free T3 (FT3), respectively.
Iodothyronine 5'- and 5-deiodinase activities
Before each assay [125I] rT3 (3,3',5'-triiodothyronine) or[125I]T4 was purified by paper electrophoresis to separate
the iodide. Iodothyronine 5'-deiodinase (5'D) activity was
assayed as described (17,19), using 2 mM DTT and 400
or 200 nM rT3 for maternal and fetal liver, respectively,
and 2 nM rT3 and 20 mM DTT for maternal and fetal
lung. Maternal and fetal brain 5'D-II activity was assayed(2,19) using 2 nM T4 + 1 /xM T3 and 20 mM DTT in the
presence of 1 mM 2-N-propyl-6-thiouracil (PTU). The
125I~ released was separated by ion exchange chromatog-
raphy on Dowex-50W-X2 columns equilibrated in 10%
acetic acid. The production of equal amounts of iodide and
3',3-T2 was checked in some assays. The protein content
was determined by the method of Lowry et al. (20), after
precipitation of the homogenates with 10% TCA to avoid
interferences from DTT in the colorimetric reaction.
Other determinations
rT3 concentrations in maternal and fetal plasma, and in
placental extracts, were determined by RIA, as previously
described (13,21).
Maternal and fetal plasma glucose levels were deter-
mined by the glucose oxidase method (22) using 10-25 pL
of plasma. Insulin levels in maternal and fetal plasma were
measured using the specific RIA adapted for rat insulin
with reagents supplied by Novo BioLabs (Denmark). We
used rat insulin as standard, anti-porcine antiserum, and
human 12sI-labeled insulin as antigen.
TSH was determined in 200-//L aliquots of maternal
plasma using the immunoreactants for RIA kindly supplied
by the National Institutes of Health (Bethesda, MD), and
made available through the Rat Pituitary Agency of the
National Institutes of Diabetes, Digestive and Kidney Dis-
eases. Concentrations are expressed in weight equivalents
of the rat TSH RP-3 reference preparation (23).
Drugs and reagents
T4, T3, 3,5-diiodothyronine (3,5-T2), PTU, and DTT
were obtained from Sigma Chemical Co. (St. Louis, MO).
rT3 and 3',3-T2 were obtained from Henning Berlin
GMBH (Berlin, Germany).
High specific activity [131I]T4, [125I]T3, [125I]T4, and[125I]rT3 (3000 pCi/pg) were synthesized in our laboratory(14,24) and used for highly sensitive T4, T3, and rT3 RIAs,
as recovery tracers for extraction, and as substrates for 5'-
deiodinases.
Statistical analysis
After testing for homogeneity of variance using Bartlett's
procedure, data were submitted to one-way analysis of
variance. Square root or logarithmic transformations usu-
ally ensured homogeneity of variance when this was not
achieved with the raw data. Significant differences among
groups were assessed using the protected least significant
difference (LSD) test. All statistical calculations were per-
formed as described by Snedecor and Cochran (25). The
SE appearing in the figures is the mean standard error cal-
culated by ANOVA, and used for the identification of sta-
tistically significant differences between groups by the LSD
test. For the sake of clarity, the ± SE is shown in figures
only on the C value bar.
RESULTS
Degree of maternal illness
Figure 1 shows the insulin and glucose concentrations in
the maternal plasma (M-plasma) from the different groups,
M- Plasma M
-
Body Weight
Glucose (mg / dl) Insulin (ng / ml) Change in g
fl 400 800 1200 0 3 « 9 12 -SO -25 0 25 50
HG. 1. Mean circulating insulin and glucose concentrations
are shown for the dams from the different groups, as well as
the calculated mean changes in the BW of the mother herself(M—BW) between 7 and 21 days of gestation, calculated as
described in the Results section, by subtracting the weight of
the conceptus from the total body weight. In this and the fol-
lowing figures, the SE shown only on the C value bar is the
mean standard error calculated by ANOVA. The shaded area
corresponds to the mean C value ± SE. An asterisk (*) iden-
tifies statistically significant differences versus C dams; num-
ber sign (#) identifies statistically significant differences ver-
sus the D group. Other statistically significant differences are
not identified for the sake of clarity.
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Table 1. Mean ( ± SEM) Increments in Total Body Weight (BW) between 7 and 21 Days of Gestation, Mean Number
of Fetuses/ Dam, BW of Fetuses (F-BW), and Weights of the Placenta (Total, Maternal and Fetal Sides), at 21
Days of Gestation, of Normal (C) and Streptozotocin-Injected Dams (D), and of D Dams Treated with Insulin (D +
Ins), or Infused with T4 (D + T4)
Group
Increment in
total weight (g)
Number of
fetuses/dam
F-body weight
(mg)
Placental weight(mg) M-placentalweight (mg)
F-placental
weight (mg)
C
D
D + Ins
D + T4
100.0 ± 2.5
31.6 ± 8.8a
71.3 ± 10.6a-b
-11.3 ±3.8ab
12.4 ± 1.0
10.0 ± 1.3
10.8 ± 1.8
6.7 ± 1.5a
4872 ± 32
3196 ± 66a
4097 ± 65ab
2746 ± 92a-b
510.6 ± 7.9
568.1 ± 12.2a
531.2 ± 14.6b
655.0 ± 40.4ab
154 ±9
116 ±4a
136 + 5
165 ± 28"
339 ± 11
361 ± 11
326 ± 11
432 ± 66a-b
Statistically significant differences (p < 0.05) versus C group.
•"Statistically significant differences (p < 0.05) versus D group.
at 21 dg. Circulating glucose levels were very high in the
STZ-injected dams, which did not receive insulin, whether
or not they were infused with T4. Insulin decreased signif-
icantly in the D dams; the infusion of T4 resulted in insulin
levels that were even lower than those of D dams. The in-
jection of insulin affected both the insulin and glucose lev-
els in the maternal circulation: Normal levels of insulin, as
measured 24 h after the last injection, were found in the
D+Ins group, with circulating glucose being somewhat
higher than C values, although markedly decreased as com-
pared to D animals.
Figure 1 also shows the calculated change in the body
weight of the pregnant rats, free of the conceptus (M-BW),
between 7 and 21 dg. The actual change of the dam plus
conceptus appears in Table 1, as well as the number of fe-
tuses per litter and the body weights of the fetuses (F-BW).
The weights of the total placenta, as well as those of the
maternal side (M-Placenta) and fetal side (F-placenta) are
also shown in Table 1. The change in M-BW was calculated
by substracting the weight of the conceptus from the mea-
sured change in total weight. The weight of the conceptus
was calculated for each animal from the sum of the weights
of all the fetuses and placentas in each dam. Although ex-
traembryonic fluids and membranes had not been collected,
the sum of the fetal and placental weights appears to be a
reasonable approximation to the total weight of the con-
ceptus. As may be seen (Fig. 1), the mean net increase in M-
BW of C dams was 27.8 ± 4.3 g. In contrast, in the D dams
there was a net loss of M-BW, which was corrected by in-
sulin treatment. The most severe loss in M-BW was found
for the D+T4 group, being more than twice that of D dams.
Both the increment in total weight (M-BW plus weight
of the conceptus) and the change in M-BW were signifi-
cantly related to decreasing glucose and increasing insulin
concentrations in the maternal circulation, and appeared
to be good indices of the degree of maternal illness. The
closest fit was found for the change in M-BW versus the
logarithm of the M-plasma insulin levels (n = 24; r = 0.76,
p < 0.001).
Effects of maternal illness on the outcome of
pregnancy
No reproductive abnormalities were observed in the con-
trol (C) group, whereas reabsorbed fetuses were found in
many D dams. Treatment with insulin prevented these ab-
normalities, whereas they were most frequent in the D+T4
dams. Either the number of fetuses per litter or the F-BW(or both) were decreased in the diabetic animals, the low-
est number and F+BW being found for the D+T4 group.
Treatment with insulin increased F-BW, but normal
weights were not achieved. Observed changes in placental
weights caused by the maternal diabetic state were great-
est in the D+T4 dams.
In summary, the outcome of pregnancy was affected by
the maternal diabetic state and illness. This was prevented,
or at least ameliorated, with the administration of 0.5 U
of insulin/100 g BW/day, and was actually worsened by
the infusion of T4 (2.4 /¿g/100 g BW per day) into the D
dams.
Effects on thyroid hormone status of the mothers
The concentrations of T4, T3, rT3, and TSH in the ma-
ternal plasma are shown in Figure 2, as well as the circu-
lating % FT4, FT4, % FT3, and FT3. Figure 3 shows the
concentrations of T4 and T3 in the liver, lung, brain, heart,
and mammary tissue.
Mean concentrations of T4, T3, and rT3 in the maternal
circulation and of T4 and T3 in most tissues studied (Figs.
2 and 3) were lower in the D dams as compared to the C
mothers, the differences being statistically significant ex-
cept for M-brain T4 and M-mamma T3. Circulating TSH(Fig. 2) was also lower in the D animals.
Maternal Plasma
T4|ng/mll %FT4 pgFT4/ml rT3 (pg/ml)
0 S 10 15 20 0.0 0.5 1.0 1.5 0 25 SO 75 100 0 50 100 ISO
c
D
D+Ins
D+T4 IM
T3(ng/ml) %FT3 pgFT3/ml TSH (ng/ml)
0 0.10.2 0.3 0.4 0.5 0.0 2.0 4.0 6.0 0.0 2.5 5.0 7.5 10.0 0 5 10 IS
C
D
-p.D+Ins-g
D+T4-H»
FIG. 2. The mean concentrations of T4, % FT4, and F T4,
T3, % FT3, and F T3, as well as rT3 and TSH in the mater-
nal circulation are shown for the different groups of dams.
See the legend to Figure 1 for the meaning of the shaded area
and of the asterisk and #.
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HG. 3. The upper panels show the concentrations of T4 in
liver, lung, brain, heart, and mamma of the dams and the bot-
tom panels the corresponding T3 concentrations, given in ng/g.
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FIG. 4. The activity of the outer-ring 5'D-deiodinases are
shown: type I for liver (pmol I~/min/mg protein) and lung(fmol I~/h/mg protein) and type II for Cx (fmol I~/h/mg pro-
tein). The meaning of the shaded areas, asterisk, and # is the
same as in the legend to Figure 1.
The circulating % FT4 was increased in the diabetic dams(Fig. 2) to twice normal values of the normal pregnant
dams. This increase was comparable to the decrease in to-
tal circulating T4, as a result of which the mean total
amount of circulating FT4, although lower in D as com-
pared to C dams, was not statistically different from that
of the C mothers. The % FT3 also increased in D as com-
pared to C dams, but not to the extent that it could com-
pensate for the decrease in circulating total T3, and the FT3
concentration was lower than that of C dams.
Treatment with insulin resulted in normal circulating T4,
T3, rT3, and TSH concentrations, and normal % FT4, FT4,
% FT3, and FT3. Thus, the maternal hypothyroxinemia
caused by the diabetic state was avoided in the insulin-
treated D dams. Treatment with insulin also reversed the
effects of the diabetic state on the concentrations of T4 and
T3 in maternal tissues, with the exception of cardiac T4.
The amount of T4 infused into the D rats effectively pre-
vented maternal hypothyroxinemia near term (Fig. 2). As
the % FT4 was markedly increased by the uncorrected di-
abetic state, the FT4 levels actually increased 2-fold as com-
pared to normal C rats. When the marked decrease in avail-
able T4 of the D dams was avoided by the infusion of T4,
circulating rT3 concentrations also increased to normal val-
ues and the rT3/T3 ratio increased 3-fold both with respect
to the C and D groups. On the contrary, total T3 and FT3
concentrations did not increase with the infusion of T4,
and were as low as in D dams. The infusion of T4 into the
D rats did not alter their very low circulating TSH. In the
T4-infused diabetic animals, the concentration of T4 in the
maternal tissues increased as compared to that of D dams.
Normal concentrations were reached in most tissues, with
higher than normal levels being reached in liver and mam-
mary tissue. As already observed for circulating T3, the
concentration of T3 in most tissues did not improve with
the infusion of T4, with T3 concentrations in the heart be-
ing actually lower than those of D dams.
5'D-I activity in the liver and lung was decreased in the
diabetic dams (Fig. 4), a finding consistent with the de-
creased hepatic and pulmonary thyroid hormone concen-
trations. Despite the decreased plasma T4 concentrations,
no significant change was observed in the 5'D-II activity
of the cortex, a finding consistent with the lack of decrease
in cerebral T4 concentration. Treatment with insulin nor-
malized liver and lung 5'D-I activities. On the contrary,
the mean 5'D-II activity in the maternal cortex decreased
with insulin treatment, but the difference with respect to
both D and C dams was not statistically significant. With
T4 treatment the activities of liver and lung 5'D-I and of
cortex 5'D-II were the same as those of D animals.
Effects on thyroid hormone status of the placenta
Figure 5 shows the concentrations of T4, T3, and rT3 in
the M- and F-placenta. As described for these iodothy-
ronines in the M-plasma, their concentrations decreased in
the D dams, and improved with insulin treatment, although
C levels were not always reached.
Treatment of the D dams with T4 increased the concen-
trations of T4 and rT3 to normal values in the F-placenta,
whereas T3 remained as low as in D dams. These changes
were similar to those observed in the M-plasma. On the
contrary in the M-placenta, T4 and rT3 levels did not reach
normal values and were lower than expected from the
changes in M-plasma T4 and rT3 values, whereas T3 was
normal and higher than expected from the changes in M-
plasma T3.
Effects in the fetus
Figure 6 shows the glucose and insulin concentrations in
F-plasma, as well as the corresponding T4 and T3 concen-
trations. F-plasma glucose was markedly elevated, and in-
sulin decreased, in the D progeny. Both were clearly ame-
liorated by treatment of the mothers with insulin, whereas
the infusion of T4 had no effect.
The concentrations of T4 and T3 in the fetal circulation
were decreased in the D group, with T4 returning to nor-
M-Placenta
0 0.5 1.0 0 12 3 4 5 6
D+Ins Cm #
D+T4
 
_ 
 
T3
D
rT3
 *
D* #
F-Placenta
0 2.5 5.0 IS 10.0 0 .1 .2 _3 .4 .5 0 0.5 1.0 1.5 2.0
 
 
HG. 5. The concentrations of T4, T3, and rT3 in the mater-
nal and fetal placenta are shown for the different groups of
dams in ng/g. The meaning of the shaded areas, asterisk, and
# is the same as indicated in the legend to Figure 1.
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Fetal Plasma
Glucose (mg/dl) Insulin Ing/ml) T4 (ng/ml) T3 (ng/ml)
0 250 500 750 1000 0 5 1.0 1.5 0 2.5 5.0 7.5 111 0 M I» IS .20
C
D
D+Ins £U *'
D+T4 : *
HG. 6. The mean concentrations of glucose and insulin in
the fetal circulation are shown, as well as the T4 and T3 lev-
els. The meaning of the shaded areas, asterisk, and # is the
same as indicated in the legend to Figure 1.
mal fetal values with insulin treatment of the mothers.
Treatment of the D dams with T4 did not improve fetal T4
concentrations and T3 levels were actually lower than those
of D fetuses.
The concentrations of T4 and T3 in different F-tissues
were decreased in the D group (Fig. 7). Treatment of the
mothers with insulin usually resulted in improved T4 and
T3 concentrations in most F-tissues, as compared to D fe-
tuses, whereas infusion of T4 into the D dams did not im-
prove the low T4 and T3 concentrations of T-tissues, with
the exception of a modest increase of F-brain T4.
The 5'D activity in F-liver and F-lung was slightly de-
creased as compared to C fetuses (Fig. 7), being restored
to normal both with insulin and T4 treatment of the moth-
ers. 5'D-II activity in the F-brain remained unchanged.
Comparison of the changes in thyroid hormone
status observed in the dams and in their fetuses
Changes in thyroid hormone status of the fetuses from
the D and insulin-treated dams were qualitatively similar
to those observed for their mothers: the concentrations of
T4 and T3 decreased in the circulation and in tissues, and
F - Liver F - Lung F - Brain
I 2 3 4 0 0.4 0.8 1.2 1.6
HG. 7. The three upper panels show the concentrations (in
ng/g) of T4 in the liver, lung, and brain of the fetuses from
the different groups of dams, with the intermediate panels
showing the corresponding T3 concentrations. The three lower
panels show the activity of the outer-ring 5'D, type I for liver(pmol I~/min/mg protein) and lung (fmol I~/h/mg protein),
and of type II for Cx (fmol I"/h/mg protein). The meaning of
the shaded areas, asterisk, and # is the same as indicated in
the legend to Figure 1.
were clearly improved when the mother was treated with
insulin. On the contrary, in fetuses from the T4-treated D
dams, the changes were different from those observed in
the T4 and T3 concentrations of the mothers. Whereas in
the mothers plasma and tissues T4 were normal, or higher
than normal, the concentrations of T4 in plasma and most
tissues of their fetuses are as low as in those of fetuses from
D dams, or even lower (i.e., F-plasma T3, Fig. 6). In this
respect, the changes of the concentrations of T4 in the fe-
tuses from D+T4 dams were similar to those observed for
T4 levels in the M-placenta.
There were very good correlations between indices of
the fetal and the maternal diabetic state, as assessed both
from the circulating glucose and the insulin concentrations.
The F-BW (Table 1) was also affected by the diabetic con-
dition of the mothers, an effect that was ameliorated, but
not totally corrected, by the administration of insulin to
the D mothers. On the contrary, treatment with T4 resulted
in even smaller fetuses than those of D mothers. The F—BW
appeared to be related to other indices of the outcome of
pregnancy, such as the number of viable fetuses per litter(« = 24; r = 0.66; p< 0.001).
DISCUSSION
Effects of STZ-induced diabetes mellitus and T4
treatment on the mother
Alterations in thyroid hormone status have been exten-
sively described for nonpregnant adult rats, treated with
STZ to induce diabetes mellitus. These are considered typ-
ical of the alterations of thyroid function and thyroid hor-
mone metabolism observed in "nonthyroidal illness"(5,6,10). At present they are considered as beneficial adap-
tive responses in situations of limited availability of intra-
cellular energy, when a decrease in T3-dependent catabolic
effects is desirable (5-7,26), although this idea is being re-
considered (26). The two best known mechanisms involved
in these responses are a decreased thyroidal secretion of
both T4 and T3, which would lower the pool of T4 avail-
able for extrathyroidal generation of T3, and a decrease in
the activity of enzymes involved in the extrathyroidal gen-
eration of T3 from T4.
The sequence of events leading to the first of these mech-
anisms appears to involve decreased release of hypothala-
mic TRH (27-29), decreased secretion of TSH(27-28,30-33), and a decreased sensitivity of the thyroid
to TSH (32). The normal feedback mechanism is super-
seded, and TSH levels actually decrease, despite the lower
levels of circulating total and/or free T4 and T3. Indeed, a
return to normal secretion of TSH, accompanied by nor-
malization of the thyroidal release of hormones, is con-
sidered as an index that the illness is remitting, or that the
metabolic alterations are under control. In the nonpreg-
nant rat with STZ-induced diabetes mellitus these mecha-
nisms are fully operative, and the decreased thyroidal pro-
duction of the iodothyronines is quantitative very
important (10).
In the present study diabetes mellitus was induced dur-
ing pregnancy. The changes in circulating total and free T4
and T3, together with decreased TSH, and the low T4 and
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T3 levels found in all the tissues studied in the present D
dams are in agreement with the changes described for the
nonpregnant diabetic rats (10), and for patients dying fromdifferent nonthyroidal illnesses (34), indicating that 2
weeks after the injection of STZ, the adaptive mechanisms
involving decreased thyroidal secretion of thyroid hor-
mones are fully operative.
With respect to the second mechanism, the direct mea-
sure of 5'D-I activities in the liver and lung of the preg-
nant D rats of the present study has confirmed that gen-
eration of T3 from T4 is decreased. Such a decrease was
also previously described for both nonpregnant (9,35,36)
and pregnant (11) diabetic rats, as well as a decreased ex-
pression of 5'D-I mRNA (35). In contrast, in agreement
with results in nonpregnant diabetic rats (37), 5'D-II ac-
tivity in the cerebral cortex of the pregnant D rats was not
changed. In other experimental situations not involving di-
abetes, however, a decrease in circulating T4 is accompa-
nied by an increase in 5'D-II activity of the cortex. This
response was not observed in the D dams, possibly because
cerebral T4 was not decreased.
Although treatment with T3 has been recently found to
be beneficial after coronary artery bypass surgery (38,39),
it is suspected that treatment with T4 is of no benefit to
patients with nonthyroidal illness (40,41). Even so, we had
not foreseen that treatment of the D dams with T4 would
actually markedly worsen their condition. Their circulat-
ing insulin levels were actually lower than those of D dams.
They clearly lost more body weight, and the outcome of
their pregnancy was very poor; their litters were the small-
est, both as regards the number and weight of the fetuses,
and the number of résorptions the greatest. This deterio-
ration could be explained if the administration of T4, in a
dose sufficient to compensate for the decreased thyroidal
secretion of hormone, increased the amount of substrate
available to 5'D-I, and more T3 might be generated as
compared to that of D dams, despite the decreased activ-
ity of the enzyme. The ensuing increase of the extrathy-
roidal T3 pool would then be expected to aggravate ^-de-
pendent catabolic events, further decreasing the availability
of intracellular energy (41).
This possible explanation is not, however, supported by
present findings, as there was no evidence whatsoever that
the T3 pools increased: T3 concentrations in plasma and
tissues were actually as low as in D dams, or even lower(i.e., heart T3 levels). This was an unexpected finding that
suggests several possible explanations. More T3 might ac-
tually have been generated and its deiodination increased,
the steady state levels of T3 remaining the same. T4 may
be having a catabolic effect per se, either through nonnu-
clear mechanism(s) of action, or by binding to nuclear re-
ceptors, which are not saturated by T3 because of the de-
creased availability of T3. Further experiments are
necessary to clarify this unexpected effect of the infusion
of T4 into D dams.
Effects of STZ-induced maternal diabetes mellitus
and T4 treatment on the fetus
Present results confirm and extend our preliminary ob-
servations on the effects of maternal STZ-induced diabetes
mellitus on fetal thyroid hormone status, as studied at 20
dg (11). The observed alterations in fetal thyroid hormone
status are likely to result from the altered carbohydrate me-
tabolism of their mothers, and from the ensuing alteration
of carbohydrate metabolism in the fetus, and not from a
direct destructive action of the STZ on the fetal pancreas.
Maternal hyperglycemia results in overstimulation and fi-
nally exhaustion of the fetal pancreas (42). When mater-
nal hyperglycemia is corrected with insulin treatment, fe-
tal glycemia and insulinemia become normal. Considering
that the placenta is impermeable to maternal insulin (43),
normalization of fetal insulinemia indicates that the fetal
pancreas had not been damaged by the injection of STZ
to their mothers.
The thyroid hormone concentrations were lower in
plasma and tissues that were obtained from fetuses of D
dams, most of these alterations improving when the ma-
ternal (and fetal) hyperglycemia improved with insulin
treatment of the mother. Despite the fact that treatment of
the dams with T4 ensured a normal maternal thyroxine-
mia, with FT4 concentrations being actually increased, T4
concentrations in the M- and F-placenta were not normal,
although higher than in the placentas from D dams. In fe-
tal plasma and tissues, T4 concentrations were as low as
in fetuses from D dams, except for a slight increase in the
F-brain, which did not, however, reach normal concentra-
tions. These findings contrast with those obtained in other
models of maternal-fetal hypothyroxinemia caused by pri-
mary thyroid failure (1). The same dose of T4 as used for
the present study, when infused into MMl-treated dams,
clearly increased the concentrations of T4 in the M- and
F-placenta, as well as in F-plasma and F-tissues, above
those of MMI fetuses from untreated dams. Maintenance
of normal T4 levels of the MMl-treated dams ensured nor-
mal T3 concentrations in the fetal brain (1). Two main fac-
tors were implied in this protective effect of maternal T4,
namely, a relatively minor increase in the amount of T4
available to the fetal brain, and a marked increase in cere-
bral 5'D-II activity. No such beneficial effects resulted from
the correction of the maternal hypothyroxinemia by treat-
ment of D dams with T4. Treatment of the D dams with
T4 did not improve the concentrations of T3 either in the
F-plasma or F-tissues, the brain included, despite the small
increase in F-brain T4. The lack of ameliorating effects on
F-brain T3 might be explained by the observed lack of re-
sponse of 5'D-II activity in the F-brain of the D fetuses.
Moreover, the infusion of T4 into the D dams had clear
negative effects on the degree of illness of the mothers, and
on the general development of the litter and individual fe-
tuses.
Unfortunately, the present results suggest that preven-
tion of the maternal hypothyroxinemia, which would be
relatively easy to accomplish, would be of little benefit, and
might actually be harmful for the development of the fe-
tus. Adequate control of the diabetes mellitus appears to
be of prime importance.
CONCLUSIONS
Present results show that maternal diabetes mellitus, and
possibly maternal nonthyroidal illnesses compromising in-
tracellular energy availability, results in severe impairment
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of the thyroid hormone status of the fetus. This includes
low cerebral concentrations of T3 during a very critical pe-
riod of brain development. Although maternal diabetes as
a cause of maternal hypothyroxinemia would be easily rec-
ognized, and controlled with insulin, other causes of ma-
ternal hypothyroxinemia might not always be evident, or
might not be promptly controlled. Correction of the ma-
ternal hypothyroxinemia by treatment with T4 might be
attempted to protect the fetal brain (1). Unfortunately, the
present results indicate that in such cases prevention of the
maternal hypothyroxinemia might be of little benefit. If the
present results are relevant for man and for causes of ma-
ternal hypothyroxinemia other than maternal diabetes, it
would appear that correction of the illness is necessary to
protect the brain, as compensatory mechanisms usually in-
volved in maintaining cerebral T3 homeostasis might not
be operative, and correction of maternal hypothyroxine-
mia, without adequate control of the illness is of no ben-
efit, and might actually be harmful. It would appear ad-
visable to take the present tentative conclusions into
consideration when faced with maternal hypothyroxinemia
caused by nonthyroid illness, and not by primary thyroid
failure.
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